Academic Journals Database
Disseminating quality controlled scientific knowledge

HDAC inhibitors in experimental liver and kidney fibrosis

Author(s): Van Beneden Katrien | Mannaerts Inge | Pauwels Marina | Van den Branden Christiane | van Grunsven Leo A

Journal: Fibrogenesis & Tissue Repair
ISSN 1755-1536

Volume: 6;
Issue: 1;
Start page: 1;
Date: 2013;
Original page

Keywords: Histone deacetylase | HDAC and liver | Kidney or hepatic | Renal fibrosis

Abstract Histone deacetylase (HDAC) inhibitors have been extensively studied in experimental models of cancer, where their inhibition of deacetylation has been proven to regulate cell survival, proliferation, differentiation and apoptosis. This in turn has led to the use of a variety of HDAC inhibitors in clinical trials. In recent years the applicability of HDAC inhibitors in other areas of disease has been explored, including the treatment of fibrotic disorders. Impaired wound healing involves the continuous deposition and cross-linking of extracellular matrix governed by myofibroblasts leading to diseases such as liver and kidney fibrosis; both diseases have high unmet medical needs which are a burden on health budgets worldwide. We provide an overview of the potential use of HDAC inhibitors against liver and kidney fibrosis using the current understanding of these inhibitors in experimental animal models and in vitro models of fibrosis.
Why do you need a reservation system?      Affiliate Program